Tuesday, January 5, 2021

IconOVir Gets $77M For Cancer Treatment Efforts

San Diego-based IconOVir bio, a biotechnology company focused on oncolytic virus therapy, has raised $77M in a Series A funding, the company announced this morning. The funding was co-led by Nextech and Vida Ventures, and also included Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Partners Venture Capital and Logos Capital. According to the company, it is working on oncolytic virus therapy to improve the treatment of patients with cancer. The company's management team founded Kite Pharma, Allogene Therapeutics, and Kronos Bio. As part of the funding, the company said that it has appointed Mark McCamish, M.D., Ph.D., as Chief Executive Officer.